Misplaced Pages

Ateganosine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 00:55, 2 January 2025 editGraeme Bartlett (talk | contribs)Administrators249,807 edits more ids← Previous edit Latest revision as of 00:56, 2 January 2025 edit undoCitation bot (talk | contribs)Bots5,436,014 edits Added bibcode. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar 
Line 108: Line 108:
| specific_rotation = | specific_rotation =
}} }}
'''Ateganosine''' is a ] inhibitor<ref name="Eglenen-Polat_2024">{{cite journal | vauthors = Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, Bender ME, Mender I, Stastny V, Drapkin BJ, Raj P, Minna JD, Xu L, Shay JW, Akbay EA | title = A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer | journal = Nature Communications | volume = 15 | issue = 1 | pages = 672 | date = January 2024 | pmid = 38253555 | pmc = 10803750 | doi = 10.1038/s41467-024-44861-8 | url = }}</ref> and ] inducer currently under investigation for the treatment of various cancers, including ] (NSCLC).<ref>{{cite web | title = Ateganosine | url = https://synapse.patsnap.com/drug/e50d8d1b96bf47c99f827aba2d529c89 | work = PatSnap }}</ref> '''Ateganosine''' is a ] inhibitor<ref name="Eglenen-Polat_2024">{{cite journal | vauthors = Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, Bender ME, Mender I, Stastny V, Drapkin BJ, Raj P, Minna JD, Xu L, Shay JW, Akbay EA | title = A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer | journal = Nature Communications | volume = 15 | issue = 1 | pages = 672 | date = January 2024 | pmid = 38253555 | pmc = 10803750 | doi = 10.1038/s41467-024-44861-8 | bibcode = 2024NatCo..15..672E | url = }}</ref> and ] inducer currently under investigation for the treatment of various cancers, including ] (NSCLC).<ref>{{cite web | title = Ateganosine | url = https://synapse.patsnap.com/drug/e50d8d1b96bf47c99f827aba2d529c89 | work = PatSnap }}</ref>


== References == == References ==

Latest revision as of 00:56, 2 January 2025

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Ateganosine
Clinical data
Other names2'-Deoxythioguanosine
Identifiers
IUPAC name
  • 2-amino-9--3H-purine-6-thione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13N5O3S
Molar mass283.31 g·mol
3D model (JSmol)
SMILES
  • C1((O1N2C=NC3=C2NC(=NC3=S)N)CO)O
InChI
  • InChI=InChI=1S/C10H13N5O3S/c11-10-13-8-7(9(19)14-10)12-3-15(8)6-1-4(17)5(2-16)18-6/h3-6,16-17H,1-2H2,(H3,11,13,14,19)/t4-,5+,6+/m0/s1
  • Key:SCVJRXQHFJXZFZ-KVQBGUIXSA-N

Ateganosine is a telomerase inhibitor and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).

References

  1. Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, et al. (January 2024). "A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer". Nature Communications. 15 (1): 672. Bibcode:2024NatCo..15..672E. doi:10.1038/s41467-024-44861-8. PMC 10803750. PMID 38253555.
  2. "Ateganosine". PatSnap.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: